Equities

OncoCyte Corp

OncoCyte Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.00
  • Today's Change0.00 / 0.00%
  • Shares traded519.00
  • 1 Year change-7.41%
  • Beta1.0110
Data delayed at least 15 minutes, as of Sep 20 2024 14:58 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy0
Outperform1
Hold2
Sell0
Strong Sell0

Share price forecast in USD

The 3 analysts offering 12 month price targets for OncoCyte Corp have a median target of 4.00, with a high estimate of 4.25 and a low estimate of 3.00. The median estimate represents a 33.33% increase from the last price of 3.00.
High41.7%4.25
Med33.3%4.00
Low0.0%3.00

Earnings history & estimates in USD

On Aug 08, 2024, OncoCyte Corp reported 2nd quarter 2024 losses of -0.36 per share. This result exceeded the -0.56 consensus loss of the 2 analysts covering the company and exceeded last year's 2nd quarter results by 66.36%.
The next earnings announcement is expected on Nov 07, 2024.
Average growth rate-5.65%
OncoCyte Corp reported annual 2023 losses of -3.75 per share on Apr 12, 2024.
Average growth rate+4.91%
More ▼

Revenue history & estimates in USD

OncoCyte Corporation had 2nd quarter 2024 revenues of 104.00k. This missed the 319.00k consensus estimate of the 2 analysts following the company. This was 64.98% below the prior year's 2nd quarter results.
Average growth rate-29.75%
OncoCyte Corporation had revenues for the full year 2023 of 1.50m. This was 73.31% below the prior year's results.
Average growth rate+145.00%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.